Alecensa 150 MG capsule UU 240S
Ended Awarded Last action
- Contract number
- SPE2DR26FKKM6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,014
Award facts
- Contract value 100% obligated
- $14,014.46 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $14,014.46 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Alecensa 150 mg capsules (240-count units). The delivery order, issued on January 23, 2026, with an ultimate completion date of February 13, 2026, carries no set-aside designation, indicating the award was made through open competitive procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group serves as a regional prime vendor under the PPV-G GEN V contract vehicle, which was awarded to the company on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036. The company's established pharmaceutical supply capabilities span branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, positioning it as a critical supplier for military healthcare operations globally. This specific delivery order for Alecensa, an oncology treatment, reflects the company's demonstrated capability to fulfill the diverse and specialized pharmaceutical requirements of the federal military medical system through the broader PPV-G GEN V acquisition framework.
Quick answers
Who was awarded contract SPE2DR26FKKM6?
SPE2DR26FKKM6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 23, 2026.
How much is contract SPE2DR26FKKM6 worth?
The government has obligated $14,014 on SPE2DR26FKKM6.
Is contract SPE2DR26FKKM6 an order under another contract?
Yes. SPE2DR26FKKM6 is a delivery order under SPE2DR25D9367, an indefinite delivery contract.
Was contract SPE2DR26FKKM6 competed?
The extent of competition for SPE2DR26FKKM6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award